Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?The Motley Fool • 02/29/24
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/28/24
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 02/28/24
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall StreetThe Motley Fool • 02/26/24
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024GlobeNewsWire • 02/22/24
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced MelanomaPRNewsWire • 02/20/24
Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In MelanomaSeeking Alpha • 02/20/24
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common StockGlobeNewsWire • 02/20/24